|会社名||Champions Oncology Inc. （チャンピオンズ・オンコロジ―）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Champions Oncology Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice along with the patient data and molecular information associated with the tumors are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company''s TumorBank. チャンピオンズ・オンコロジ―は米国のバイオ医薬品・サ―ビス企業。がん治療に対する薬剤と技術サ―ビスの開発と商品化に従事する。人間のがん腫瘍をマウスに移植し開発する「TumorGraft」テクロノジ―は、個別のがん患者に合う治療を提供。事業は、医師・患者向けと製薬・バイオ医薬品企業向けの2分野で構成。本社はニュ―ジャ―ジ―州。 Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.|
|本社所在地||One University Plaza Suite 307 Hackensack NJ 07601 USA|
|代表者氏名||Joel Ackerman ジョエルアッカーマン|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the three months ended 31 July 2018 Champions Oncology Inc revenues increased 24% to $6.2M. Net income totaled $482K vs. loss of $674K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Sales and marketing decrease of 24% to $518K (expense) General and administrative decrease of 13% to $1.1M (expense).|
Champions Oncology, Inc.: Champions Oncology to Announce First Quarter Financial Results on Monday, September 13, 2021 2021/09/02 20:32:00 FinanzNachrichten
HACKENSACK, NJ / ACCESSWIRE / September 2, 2021 / Champions Oncology, Inc. (CSBR), leaders in transformative technology solutionsutilized in oncology drug discovery and development will report its
Global Humanized Mice Model Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Ingenious Targeting Laboratory, Axen, rans Genic Inc., Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Genoway S.A., Crown Bioscience Inc., Taconic Biosciences Inc., The Jackson Laboratory, Vitalstar Biotechnology Co. Ltd.ÃÂ 2021/07/23 21:35:05 Jumbo News
The report on Global Humanized Mice Model Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic 
Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $10.6 Million 2021/07/22 12:08:00 FinanzNachrichten
Record Annual Revenue of $41 MillionHACKENSACK, NJ / ACCESSWIRE / July 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in d
Champions Oncology, Inc.: Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 22, 2021 2021/07/14 12:32:00 FinanzNachrichten
HACKENSACK, NJ / ACCESSWIRE / July 14, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovati
The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes 2021/03/17 11:43:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16) Affimed N.V. (NASDAQ: AFMD ) BioAtla, Inc. (NASDAQ: BCAB ) Champions Oncology, Inc. (NASDAQ: CSBR ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Omnicell, Inc. (NASDAQ: OMCL ) Savara Inc. (NASDAQ: SVRA ) (reacted to a positive analyst action and insider buying) Sierra Oncology, Inc. (NASDAQ: SRRA ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 16) Galecto, Inc. (NASDAQ: GLTO ) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus Pfizer to Sell Chinese Biologics Unit to WuXi Pfizer Inc.'s (NYSE: PFE ) China unit and Hong Kong-listed WuXi Biologics announced an equity agreement under which the latter will acquire the former's state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
Champions Oncology (NASDAQ:CSBR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS 2021/03/13 03:48:41 Transcript Daily
Champions Oncology (NASDAQ:CSBR) posted its quarterly earnings data on Wednesday. The biotechnology company reported $0.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.04, Fidelity Earnings reports. Champions Oncology had a negative return on equity of 29.93% and a negative net margin of 4.18%. Shares of NASDAQ CSBR traded up […]
The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted 2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration 2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q4 2020 Results - Earnings Call Transcript 2020/07/27 23:24:03 Seeking Alpha
Champions Oncology, Inc. (NASDAQ:CSBR) Q4 2020 Results Earnings Conference Call July 27, 2020, 4:30 pm ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Scott Henry - ROTH Capital Presentation Operator Greetings and welcome to Champions Oncology fourth quarter fiscal year 2020 earnings call.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 チャンピオンズ・オンコロジ― CSBR Champions Oncology Inc.）